{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:31:33Z","timestamp":1786649493291,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose:<\/jats:title>\n                    <jats:p>\n                      The PD-1\/PD-L1 immune checkpoint pathway inhibits T cell function, allowing tumors to escape immune responses. This study aimed to reprogram this inhibitory signaling using a PD- 1:CD28 switch receptor (SR) to convert inhibitory signaling into a co-stimulatory signal and to assess its effects on the function of CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental approach:<\/jats:title>\n                    <jats:p>\n                      PBMCs isolated from both sources were retrovirally transduced with PD-1:CD28 SR. Intracellular expression of cytokines, including IFN-\u03b3, IL-4, IL-10, as well as the surface CD25 in CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, and the rate of cell apoptosis during engineering and exposure to target cells were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings\/Results:<\/jats:title>\n                    <jats:p>\n                      Both buffy coat (BC) and whole blood showed comparable transduction efficiency (21.4% versus 18.5%, respectively), but BC yielded nearly double the number of viable PBMCs per 50 mL. Upon stimulation and co-culture with target cells, CD4\n                      <jats:sup>+<\/jats:sup>\n                      SR T cells produced significantly higher levels of IFN-\u03b3, IL-4, and IL-10 compared to CD8\n                      <jats:sup>+<\/jats:sup>\n                      SR T cells. These cytokines also significantly increased in co-culture supernatants exposed to PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      cells. No significant differences were found in CD4\/CD8 ratios, CD25 expression, or cytokine profiles between PBMC sources. However, BC-derived T cells showed higher apoptosis rates during co-culture.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and implications:<\/jats:title>\n                    <jats:p>\n                      BC can be a practical and effective source of PBMCs for T cell engineering. These findings underscore the SR signaling in the activation of CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells that may impact the activation of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, which is essential for effective tumor eradication.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/rps.rps_82_25","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:00:20Z","timestamp":1777176020000},"page":"236-250","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets"],"prefix":"10.4103","volume":"21","author":[{"given":"Saba","family":"Feghhi-Najafabadi","sequence":"first","affiliation":[{"name":"Department of Immunology, Pasteur Institute of Iran, Tehran, I.R. Iran"},{"name":"Student Research Committee, Pasteur Institute of Iran, Tehran, I.R. Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Riazi-Rad","sequence":"additional","affiliation":[{"name":"Department of Immunology, Pasteur Institute of Iran, Tehran, I.R. Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Shokrgozar","sequence":"additional","affiliation":[{"name":"National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, I.R. Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriyar","family":"Abdoli","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, I.R. Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Hajari","family":"Taheri","sequence":"additional","affiliation":[{"name":"Food and Drug Laboratory Research Center (FDLRC), Food and Drug Administration, Iran Ministry of Health and Medical Education, Tehran. I.R. Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Arashkia","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology, Pasteur Institute of Iran, Tehran, I.R. Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sharifzadeh","sequence":"additional","affiliation":[{"name":"Department of Immunology, Pasteur Institute of Iran, Tehran, I.R. Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"R1-20260429","doi-asserted-by":"crossref","first-page":"868695,1","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"R2-20260429","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4103\/1735-5362.323911","article-title":"Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer","volume":"16","author":"Rahimmanesh","year":"2021","journal-title":"Res Pharm Sci"},{"issue":"12","key":"R3-20260429","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"6382","key":"R4-20260429","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"R5-20260429","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4103\/RPS.RPS_28_23","article-title":"The effect of redox bacteria on the programmed cell death-1 cancer immunotherapy","volume":"19","author":"Nejati","year":"2024","journal-title":"Res Pharm Sci"},{"issue":"22","key":"R6-20260429","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"R7-20260429","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune- related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"5&6","key":"R8-20260429","doi-asserted-by":"crossref","first-page":"221","DOI":"10.61186\/ibj.4444","article-title":"A systematic review on the dual role of interleukin- 1 in CAR T-cell therapy: enhancer and mitigator","volume":"28","author":"Maali","year":"2024","journal-title":"Iran Biomed J"},{"issue":"8","key":"R9-20260429","doi-asserted-by":"crossref","first-page":"djv146,1","DOI":"10.1093\/jnci\/djv146","article-title":"Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy","volume":"107","author":"Kobold","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"R10-20260429","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41590-023-01658-z","article-title":"Harnessing CD3 diversity to optimize CAR T cells","volume":"24","author":"Velasco C\u00e1rdenas","year":"2023","journal-title":"Nat Immunol"},{"issue":"6332","key":"R11-20260429","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"16","key":"R12-20260429","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2217\/imt-2017-0103","article-title":"Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers","volume":"9","author":"Tay","year":"2017","journal-title":"Immunotherapy"},{"issue":"6","key":"R13-20260429","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T- Cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"issue":"2","key":"R14-20260429","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD- 1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"R15-20260429","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"R16-20260429","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.21037\/tcr-23-2044","article-title":"The role of CD4+ CAR T cells in cancer immunotherapy","volume":"13","author":"Bove","year":"2024","journal-title":"Transl Cancer Res"},{"key":"R17-20260429","doi-asserted-by":"crossref","first-page":"972021,1","DOI":"10.3389\/fimmu.2022.972021","article-title":"Roles of CD4+ T cells as mediators of antitumor immunity","volume":"13","author":"Kravtsov","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"R18-20260429","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF00812261","article-title":"Th1\/Th2 balance in cancer, transplantation and pregnancy","volume":"21","author":"Shurin","year":"1999","journal-title":"Springer Semin Immunopathol"},{"issue":"9","key":"R19-20260429","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8+ T cell subsets in antitumor immunity","volume":"30","author":"Paul","year":"2020","journal-title":"Trends Cell Biol"},{"issue":"3","key":"R20-20260429","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4049\/jimmunol.172.3.1380","article-title":"Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses","volume":"172","author":"Dobrzanski","year":"2004","journal-title":"J Immunol"},{"issue":"6","key":"R21-20260429","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4049\/jimmunol.150.6.2121","article-title":"Distinction of mouse CD8+ suppressor effector T cell clones from cytotoxic T cell clones by cytokine production and CD45 isoforms","volume":"150","author":"Inoue","year":"1993","journal-title":"J Immunol"},{"issue":"1-2","key":"R22-20260429","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"R23-20260429","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/clim.2000.4902","article-title":"Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T- cells during aging","volume":"96","author":"Laux","year":"2000","journal-title":"Clin Immunol"},{"issue":"5796","key":"R24-20260429","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"8","key":"R25-20260429","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/CJI.0b013e3181f1d644","article-title":"The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy","volume":"33","author":"Tumeh","year":"2010","journal-title":"J Immunother"},{"issue":"5","key":"R26-20260429","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/1735-5362.297846","article-title":"The challenging nature of primary T lymphocytes for transfection: effect of protamine sulfate on the transfection efficiency of chemical transfection reagents","volume":"15","author":"Rahimmanesh","year":"2020","journal-title":"Res Pharm Sci"},{"issue":"2","key":"R27-20260429","doi-asserted-by":"crossref","first-page":"020708,1","DOI":"10.11613\/BM.2019.020708","article-title":"Effect of temperature and time delay in centrifugation on stability of select biomarkers of nutrition and non-communicable diseases in blood samples","volume":"29","author":"Abraham","year":"2019","journal-title":"Biochem Med (Zagreb)"},{"key":"R28-20260429","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-9036-8_2","article-title":"Isolation of human peripheral blood T-lymphocytes","volume":"1930","author":"Kizhakeyil","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"2","key":"R29-20260429","doi-asserted-by":"crossref","first-page":"364,1","DOI":"10.3390\/cells9020364","article-title":"Mechanotransduction in T cell development, differentiation and function","volume":"9","author":"Rushdi","year":"2020","journal-title":"Cells"},{"issue":"3","key":"R30-20260429","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cels.2019.01.006","article-title":"Mechanical force induces phosphorylation-mediated signaling that underlies tissue response and robustness in xenopus embryos","volume":"8","author":"Hashimoto","year":"2019","journal-title":"Cell Syst"},{"key":"R31-20260429","doi-asserted-by":"crossref","first-page":"2638,1","DOI":"10.3389\/fimmu.2018.02638","article-title":"Role of mechanotransduction and tension in T cell function","volume":"9","author":"Rossy","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"R34-20260429","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3892\/ol.2020.11757","article-title":"Interferon-\u03b3 induced PD-L1 expression and soluble PD-L1 production in gastric cancer","volume":"20","author":"Imai","year":"2020","journal-title":"Oncol Lett"},{"key":"R35-20260429","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0421s37","article-title":"Production and titration of lentiviral vectors","author":"Salmon","year":"2006","journal-title":"Curr Protoc Neurosci"},{"issue":"1","key":"R36-20260429","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked chimeric antigen receptor for tumor- specific activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol Ther"},{"issue":"11","key":"R37-20260429","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.4049\/jimmunol.174.11.6648","article-title":"Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell- mediated alloimmune responses in vivo","volume":"174","author":"Ito","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"R38-20260429","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1365-2990.1998.00120.x","article-title":"Differential expression of MHC class II molecules by microglia and neoplastic astroglia: relevance for the escape of astrocytoma cells from immune surveillance","volume":"24","author":"Tran","year":"1998","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"R39-20260429","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"issue":"7","key":"R40-20260429","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1172\/JCI24624","article-title":"Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma","volume":"115","author":"Kaufman","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"R41-20260429","doi-asserted-by":"crossref","first-page":"30,1","DOI":"10.1186\/s12865-022-00505-4","article-title":"Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry","volume":"23","author":"Li","year":"2022","journal-title":"BMC Immunol"},{"issue":"1-2","key":"R42-20260429","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0022-1759(03)00231-X","article-title":"Simple and cost- effective isolation of monocytes from buffy coats","volume":"278","author":"Repnik","year":"2003","journal-title":"J Immunol Methods"},{"issue":"4","key":"R43-20260429","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/trf.14532","article-title":"Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems","volume":"58","author":"Szczepiorkowski","year":"2018","journal-title":"Transfusion"},{"issue":"1","key":"R44-20260429","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1084\/jem.192.1.117","article-title":"Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells","volume":"192","author":"Dalton","year":"2000","journal-title":"J Exp Med"},{"issue":"7","key":"R45-20260429","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.20020666","article-title":"Interferon gamma is required for activation-induced death of T lymphocytes","volume":"196","author":"Refaeli","year":"2002","journal-title":"J Exp Med"},{"issue":"2","key":"R46-20260429","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4049\/jimmunol.179.2.939","article-title":"IFN-\u03b3 acts directly on activated CD4+ T cells during mycobacterial infection to promote apoptosis by inducing components of the intracellular apoptosis machinery and by inducing extracellular proapoptotic signals","volume":"179","author":"Li","year":"2007","journal-title":"J Immunol"},{"issue":"9","key":"R47-20260429","first-page":"101161,1","article-title":"A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy","volume":"4","author":"Boulch","year":"2023","journal-title":"Cell Rep Med"},{"issue":"21","key":"R48-20260429","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1158\/0008-5472.CAN-10-1322","article-title":"CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes","volume":"70","author":"Bos","year":"2010","journal-title":"Cancer Res"},{"issue":"3-4","key":"R49-20260429","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","article-title":"Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor","volume":"51","author":"Prosser","year":"2012","journal-title":"Mol Immunol"},{"issue":"1955","key":"R50-20260429","first-page":"1","article-title":"PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin lymphoma","volume":"9","author":"Rataj","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"R51-20260429","doi-asserted-by":"crossref","first-page":"e12635,1","DOI":"10.1371\/journal.pone.0012635","article-title":"Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells","volume":"5","author":"Rajasekaran","year":"2010","journal-title":"PloS One"},{"key":"R52-20260429","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"6852","key":"R53-20260429","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/35093109","article-title":"Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity","volume":"413","author":"Diefenbach","year":"2001","journal-title":"Nature"},{"issue":"7","key":"R54-20260429","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/ijc.24098","article-title":"Interferon-gamma down- regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells","volume":"124","author":"Schwinn","year":"2009","journal-title":"Int J Cancer"},{"issue":"11","key":"R55-20260429","doi-asserted-by":"crossref","first-page":"e007803,1","DOI":"10.1136\/jitc-2023-007803","article-title":"CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"R56-20260429","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"issue":"12","key":"R57-20260429","doi-asserted-by":"crossref","first-page":"e003176,1","DOI":"10.1136\/jitc-2021-003176","article-title":"Switch receptor T3\/28 improves long-term persistence and antitumor efficacy of CAR-T cells","volume":"9","author":"Zhao","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"R58-20260429","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.168.1.1","article-title":"Cutting Edge: IL- 10-producing CD4+ T cells mediate tumor rejection","volume":"168","author":"Segal","year":"2002","journal-title":"J Immunol"},{"issue":"11","key":"R59-20260429","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"}],"container-title":["Research in Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_82_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:46Z","timestamp":1786647286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_82_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/rps.rps_82_25","relation":{},"ISSN":["1735-5362","1735-9414"],"issn-type":[{"value":"1735-5362","type":"print"},{"value":"1735-9414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-05-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}